Floatz logo

Tagraxofusp

Plasma Cell Myeloma

Stemline Therapeutics, Inc.protein_peptidePhase 1/2Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
59/ 100

Competitive context

498 Active assets in the Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB
CYCLOSPORIN A
Seoul National University Hospital
Phase 3BBB
VINCRISTINE SULFATE
Roswell Park Cancer Institute
Phase 3BBB
Anti-Thymoglobulin, Rabbit
University of Birmingham
Phase 4BBB

View all 50 →

Same molecule, other indications

Tagraxofusp is also rated in:

CD4+/CD56+ hematodermic neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
56 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →